17,261 trials
Relapsed Solid Tumor · Refractory Solid Tumor
Primary: Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) — 55 milligrams/squared meters (mg/m²) BID
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma · Classical Hodgkin Lymphoma
Primary: Maximum Tolerable Dose (Phase I) — NA Participants
Heart Failure, Systolic · Inflammation
Primary: Changes in Peak Oxygen Consumption (VO2) — 1.50; 1.20 mL/kg/min — p=0.60
Hunter Syndrome
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 4; 10; 5 Participants
Pancreatic Cancer Stage IV
Primary: Number of Participants With Progression Free Survival (PFS) — 1 participants
Muscle Injury · Recovery · Pain Relief
Primary: Self-report Ratings of Muscle Soreness — 0.0; 0.0 score on a scale
Myelodysplastic Syndrome (MDS) · Chronic Lymphocytic Leukemia (CLL) · Chemotherapy-sensitive Lymphoma
Primary: Overall Survival — 72.3; 78.9 percentage of participants
Diabetic Macular Edema · Retinal Disease · Macular Edema
Primary: Mean Change From Baseline to Average of Week 20 and Week 24 in BCVA by ETDRS Letter — 5.1; 3.7 change in ETDRS letters
Group B Streptococcus Infections
Primary: Percentage of Participants Reporting Local Reactions Within 7 Days After Primary Dose: Non-Pregnant Participants Stage 1 — 27.3; 27.3; 13.6; 22.7 Percentage of…
Chronic Intestinal Pseudo-obstruction
Primary: Mean Change in Weekly Global Gastrointestinal Symptoms Average Index Score (WGGSAIS). — -0.424; -0.185 score — p==0.1279
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Urinary Bladder Neoplasms
Primary: Cohort 1: Recurrence-Free Survival (RFS) — NA; 11.60 Months — p==0.0007
Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Lymphoma, Mantle-Cell
Primary: Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at…
Opioid-use Disorder
Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants